A Novel Index Consisting of Age, CA19-9, and Methylated Somatostatin Is Useful for Diagnosing Early Pancreatic Cancer.

Authors

Shoko Tabara, Yutaka Suehiro, Harumi Suehiro, Ukyo Shinagawa, Kaori Hamamoto, Takanori Tsuyama, Shuhei Shinoda, Shigeyuki Suenaga, Yuki Kunimune, Ikuei Fujii, Chieko Suzuki, Shingo Higaki, Taro Takami, Takahiro Yamasaki

Published in

Cancer medicine. Volume 15. Issue 8. Pages e72202.

Abstract

There are no reliable screening tests for pancreatic ductal adenocarcinoma (PDAC). We performed this study to address this issue. Using 206 serum samples from 95 healthy subjects and 111 patients with PDAC, we developed the novel ACAm-S index, which consists of age, CA19-9, and methylated somatostatin. The ACAm-S index showed a sensitivity of 91.0% (101/111) for all stages of PDAC and a specificity of 94.7% (90/95). Notably, its sensitivity was high at 85.4% (35/41), even for Stage I PDAC. The ACAm-S index may have potential as a blood-based screening tool for early-stage PDAC in the general population.

PMID:
42630043
Bibliographic data and abstract were imported from PubMed on 22 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.